Evidence of the contribution of pharmaceutical care in the study and management of chronic pain
Evidência da contribuição do cuidado farmacêutico no estudo e manejo da dor crônica
Maia e Maia Fischel e Andrade; Ricardo Radighieri Rascado; Luciano Maia Alves Ferreira; Marcelo Lourenço da Silva
Abstract
Keywords
Resumo
Palavras-chave
References
1 Braga PDA, Alves LP, Mendes RS, Campos DCL. Farmácia clínica baseada em evidências. São Paulo: Manole; 2023.
2 Caetano MC, Silva RM, Luiza VL. Serviços farmacêuticos na atenção primária em saúde à luz do modelo ambiguidade-conflito. Physis. 2020;30(4):e300420.
3 Ciola G, Silva MS, Neri AL, Borim FSA. Dor crônica em idosos e associações diretas e indiretas com variáveis sociodemográficas e de condições de saúde. Rev Bras Geriatr Gerontol. 2020;23(3):e200065.
4 Costa KS, Tavares NUL, Nascimento JM Jr, Mengue SS, Álvares J, Guerra AA Jr, Acurcio FA, Soeiro OM. Avanços e desafios da assistência farmacêutica na atenção primária no Sistema Único de Saúde: advances and challenges. Rev Saude Publica. 2017;51(suppl 2):3s.
5 Raja SN, Carr DB, Cohen M, Finnerup NB, Flor H, Gibson S, Keefe FJ, Mogil JS, Ringkamp M, Sluka KA, Song XJ, Stevens B, Sullivan MD, Tutelman PR, Ushida T, Vader K. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain. 2020;161(9):1976-82.
6 Araújo PS, Costa EA, Guerra AA Jr, Acurcio FA, Guibu IA, Álvares J, Costa KS, Karnikowski MGO, Soeiro MS, Leite SN. Atividades farmacêuticas de natureza clínica na atenção básica no Brasil. Rev Saude Publica. 2017;51(suppl 2):6s-13s.
7 Vismari L, Palma VC, Carvalho MFC, Luppi G. Acompanhamento farmacoterapêutico na dor crônica geriátrica: relato de caso. Rev Kairós-Gerontologia. 2017;20(23):251-69.
8 Blondal AB, Sporrong SK, Almarsdottir AB. Introducing pharmaceutical care to primary care in Iceland: na action research study. Pharmacy. 2017;5(2):23.
9 Cazarim MS, Freitas O, Penaforte AAR, Pereira LRL. Impact of pharmaceutical care on the management of hypertension and coronary risk factors after discharge. PLoS One. 2016;11(6):e0155204.
10 Morillo-Verdugo R, Calleja-Hernández MA, Robustillo-Cortés MA, Poveda-Andrés AL. Una nueva definición y reenfoque de la atención farmacéutica: el Documento de Barbate. Farm Hosp. 2020;44(4):158-62. PMid:32646347.
11 Aguiar DP, Souza CPQ, Barbosa WJM, Santos FFU Jr, Oliveira AS. Prevalência de dor crônica no Brasil: revisão sistemática. BrJP. 2021;4(3):257-67.
12 Jabri FF, Liang Y, Alhawassi TM, Johnell K, Möller J. Potentially inappropriate medications in older adults – prevalence, trends and associated factors: a cross-sectional study in Saudi Arabia. Healthcare (Basel). 2023;11(14):2003.
13 Barad M, Aggarwal A. Avaliação da dor. In: Barath M, editor. Manuais MSD, edição para profissionais [Internet]. Rahway: Merck & Co, Inc.; 2025 [citado 2025 jun 12].
14 Didone TVN, Delgado PG, Melo DO, Romano-Lieber NS, Martínez FM, Ribeiro E. Validation of the “Conocimiento del Paciente sobre sus Medicamentos” (CPM-ES-ES) questionnaire: evaluation of pharmaceutical services in primary health care of the Brazilian Unified Health System. Cien Saude Colet. 2019;24(9):3539-50.
15 Farré Riba R, Clopes Estela A, Sala Esteban ML, Gámez Lechuga M, López Sáncez S, Tomás Sanz R, Alba Aranda G, Castillo Álvarez F, García Peláez M, Montejo Arcusa O, Serra Soler G, Sanz Mazó M. Intervenciones farmacéuticas (parte I): metodología y evaluación. Farm Hosp. 2000;24(3):136-44.
16 Dellaroza MSG, Pimenta CAM, Matsuo T. Prevalência e caracterização da dor crônica em idosos não institucionalizados. Cad Saude Publica. 2007;23(5):1141-50.
17 Council of Europe. Resolution CM/Res(2020)3 on the implementation of pharmaceutical care for the benefit of patients and health services. Strasbourg: Council of Europe; 2020.
18 Pharmaceutical Care Network Europe. Classification for drug-related problems V9.0. Basel: PCNE; 2019.
19 Al-Hashel JY, Ahmed SF, Alshawaf FJ, Alroughani R. Use of traditional medicine for primary headache disorders in Kuwait. J Headache Pain. 2018;19(1):118.
20 Thapa N, Bhuvan KC, Gyawali S, Leong SL, Mohamed Ibrahim MI, Lee SWH. Effectiveness of community pharmacist-led interventions in osteoarthritis pain management: a cluster-randomized trial. Res Social Adm Pharm. 2024;20(2):149-56.
21 Dayer L, Heldenbrand S, Anderson P, Gubbins PO, Martin BC. Pharmacist interventions in chronic pain management: a systematic review and meta-analysis. Res Social Adm Pharm. 2023;19(1):11-21.
22 Zheng X, Ding H, Xu S, Xie R, Liu Y, Li Y, Zhai Q, Fang L, Tong Y, Sun J, Xin W, Wu N, Chen J, Shi W, Yang L, Li H, Shao J, Wang Y, Yu H, Zhang B, Du Q, Yang Y, Zhang H, Gong L, Zhang Y, Song Z, Yang Y, Zhou S, Huang C, Lin J, Wang C, Huang X, Wi Q, Sun Y, Huang P. Pharmacist-led management improves treatment adherence and quality of life in opioid-tolerant patients with cancer pain: A randomized controlled trial. Pain Ther. 2022;11(1):241-52.
23 Shrestha S, Iqbal A, Teoh SL, Khanal S, Gan SH, Lee SWH, Paudyal V. Impact of pharmacist-delivered interventions on pain-related outcomes: an umbrella review of systematic reviews and meta-analyses. Res Social Adm Pharm. 2024;20(6):34-51.
24 Bennett MI, Bagnall AM, Raine G, Closs SJ. Educational interventions by pharmacists to patients with chronic pain: systematic review. Clin J Pain. 2011;27(7):623-30.
Submitted date:
06/12/2025
Accepted date:
11/21/2025

